

Alt # 18

Substitute for form 1449A/PTO  <div style="display: flex; align-items: center;"> <div style="border: 2px solid black; border-radius: 50%; padding: 10px; text-align: center; margin-right: 10px;">           O I P E            MAR 12 2002            U.S. PATENT &amp; TRADEMARK OFFICE         </div> <div> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>            (use as many sheets as necessary)         </div> </div>		<b>Complete if Known</b> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%;">Application No.</td> <td>09/391,861</td> </tr> <tr> <td>Filing Date:</td> <td>September 7, 1999</td> </tr> <tr> <td>First Named Inventor</td> <td rowspan="3" style="text-align: center; vertical-align: middle; font-size: 2em; font-weight: bold;">RECEIVED</td> </tr> <tr> <td>Group Art Unit</td> </tr> <tr> <td>Examiner Name</td> </tr> <tr> <td>Attorney Docket No.</td> <td>MAR 20 2002 99,371</td> </tr> </table>		Application No.	09/391,861	Filing Date:	September 7, 1999	First Named Inventor	RECEIVED	Group Art Unit	Examiner Name	Attorney Docket No.	MAR 20 2002 99,371
Application No.	09/391,861												
Filing Date:	September 7, 1999												
First Named Inventor	RECEIVED												
Group Art Unit													
Examiner Name													
Attorney Docket No.	MAR 20 2002 99,371												
Sheet 1 of 2													

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
or		WO	01/32678	A	Smithkline Beecham Corporation	05/10/2001		
J		WO	01/38357	A2	Millennium Pharmaceuticals, Inc.	05/31/2001		
		WO	01/36640	A2	Chiron Corporation	05/25/2001		
		WO	01/18209	A1	Curagen Corporation	05/15/2001		
		WO	01/49849	A1	Zymogenetics, Inc.	07/12/2001		
		WO	00/54813	A2	Chiron Corporation	09/21/00		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
R		Accession Number: AB006136, 27 August 1997, XP002165898.	
J		Accession Number: AQ175436, 21 September 1998, XP002188227.	
J		Accession Number: AV050323, 16 June 1999, XP002165897.	

	4/4/03	
--	--------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for Form 1449A/P <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application No.	09/391,861
		Filing Date:	September 7, 1999
		First Named Inventor	Thomason et al.
		Group Art Unit	1633
		Examiner Name	D. Nguyen
Sheet 2 of 2	Attorney Docket No.	MAR 27 2002	

TECH CENTER 1600/2900

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
DA		GALZIE Z. et al., "Fibroblast Growth Factors and their Receptors", Biochemistry and Cell Biology, vol. 75, no. 6, 1997, pages 669-685.	
↓		SMALLWOOD P.M. et al., "Fibroblast Growth Factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development", Proceedings of the National Academy of Sciences of the USA, vol. 93, September 1996 pages 9850-9857.	

Examiner Signature	DA	Date Considered	4/4/03
--------------------	----	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231